哈三联(002900) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached ¥315,082,371.76, an increase of 10.46% compared to the same period last year[1]. - Net profit attributable to shareholders was ¥14,311,564.79, representing a significant increase of 80.36% year-over-year[1]. - The net profit after deducting non-recurring gains and losses was ¥11,966,635.72, up 75.96% from the previous year[1]. - Total operating revenue for Q3 2024 was CNY 838.53 million, a decrease of 9.1% compared to CNY 922.46 million in Q3 2023[11]. - Operating profit for Q3 2024 was CNY 40.69 million, down 35.2% from CNY 62.74 million in Q3 2023[12]. - Net profit attributable to shareholders of the parent company for Q3 2024 was CNY 40.58 million, a decline of 32.6% from CNY 60.12 million in Q3 2023[12]. - The basic earnings per share for Q3 2024 was CNY 0.13, down from CNY 0.19 in Q3 2023[12]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥3,555,038,975.76, reflecting a growth of 3.25% compared to the end of the previous year[1]. - Total assets increased to CNY 3.56 billion in Q3 2024 from CNY 3.44 billion in Q3 2023, representing a growth of 3.2%[10]. - Total liabilities rose to CNY 1.41 billion in Q3 2024, up 8.8% from CNY 1.29 billion in Q3 2023[10]. - Cash and cash equivalents decreased from ¥991,162,246.58 to ¥765,304,402.24, a decline of approximately 22.8%[8]. - The company’s cash and cash equivalents decreased to CNY 1.09 billion in Q3 2024 from CNY 1.08 billion in Q3 2023[10]. Cash Flow - The company's cash flow from operating activities showed a negative net amount of ¥45,120,146.94, a decline of 264.82% year-over-year[1]. - The net cash flow from operating activities for the current period is -45,120,146.94 RMB, a decrease from 27,375,873.49 RMB in the previous period[14]. - Total cash inflow from operating activities is 868,071,771.42 RMB, down from 996,854,505.38 RMB year-over-year[14]. - Cash outflow from operating activities totaled 913,191,918.36 RMB, compared to 969,478,631.89 RMB in the previous period[14]. - Cash inflow from investment activities is 225,785,193.74 RMB, significantly higher than 85,277,776.80 RMB in the previous period[14]. - The net cash flow from investment activities is -278,266,250.20 RMB, worsening from -195,984,495.98 RMB year-over-year[14]. - Cash inflow from financing activities reached 892,280,976.55 RMB, compared to 276,330,000.00 RMB in the previous period[14]. - The net cash flow from financing activities improved to 304,959,417.97 RMB from -17,910,713.58 RMB in the previous period[14]. - The ending balance of cash and cash equivalents is 523,931,302.90 RMB, down from 595,750,292.02 RMB in the previous period[14]. - The company received 680,541,567.60 RMB in cash from borrowings, a significant increase from 275,000,000.00 RMB in the previous period[14]. - The company paid 472,535,000.00 RMB in cash to repay debts, compared to 230,131,000.00 RMB in the previous period[14]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 30,555[7]. - The company has a significant shareholder, Qin Jianfei, holding 39.10% of shares[7]. - The company is controlled by Qin Jianfei and Zhou Li, who are husband and wife[7]. Expenses - Sales expenses decreased by 42.80% to ¥207,007,752.29, influenced by ongoing policies related to centralized drug procurement[3]. - Research and development expenses for Q3 2024 were CNY 75.54 million, slightly down from CNY 77.76 million in Q3 2023[11]. - The company reported a decrease in sales expenses to CNY 207.01 million in Q3 2024 from CNY 361.87 million in Q3 2023, a reduction of 42.7%[11]. - Financial expenses increased by 91.01% to -4,115,858.13 due to higher interest expenses from increased short-term and long-term borrowings[4]. Impairment Losses - Credit impairment losses decreased by 76.61% to 198,514.22, reflecting a reduction in the reversal of bad debt provisions for accounts receivable[4]. - Asset impairment losses increased by 217.49% to -1,204,816.81, mainly due to provisions for inventory write-downs[4]. - Fair value changes resulted in a loss of -7,446,718.86, a decrease of 174.21% compared to the previous year, primarily due to reduced gains from securities investments[4]. Receivables and Inventory - The accounts receivable rose by 57.22% to ¥149,367,483.03, primarily due to increased sales on credit by a subsidiary[3]. - Accounts receivable increased from ¥95,004,702.81 to ¥149,367,483.03, an increase of approximately 57.1%[8]. - Inventory increased from ¥208,787,058.53 to ¥247,824,069.46, an increase of approximately 18.7%[8]. - Total current assets decreased from ¥1,436,438,737.22 to ¥1,341,127,834.15, a decline of approximately 6.6%[8]. - Long-term equity investments increased from ¥708,987,719.21 to ¥713,806,911.68, an increase of approximately 0.5%[8]. - Fixed assets increased from ¥764,872,214.02 to ¥769,427,532.56, an increase of approximately 0.7%[8]. - The company has a total of 15 million yuan in long-term receivables, which was not present in the previous period[8].